文献速递神经核医学

主观认知下降个体基线淀粉样蛋白PET定量可识别淀粉样蛋白累积和认知恶化风险:FACEHBI研究

Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-23

研究纳入197例主观认知下降个体,其中118例完成三次[18F]florbetaben扫描、79例完成两次扫描,随访5年。基线淀粉样蛋白负荷较高、年龄较大和受教育程度较低的个体MCI转化风险增加;基线Aβ-组中19%的N1个体(CL≤13.5)仍出现淀粉样蛋白累积,N2组(13.5<CL≤20)89%累积,GZ组全部累积且累积率最高(5.1 CL/年)。基线淀粉样蛋白水平可区分随时间累积淀粉样蛋白并存在认知下降风险的个体,包括亚阈值Aβ水平者。

要点

  • 基线淀粉样蛋白负荷较高、年龄较大和受教育程度较低的SCD个体MCI转化风险增加。
  • CL≤13.5的N1组中19%个体随访期间仍出现淀粉样蛋白累积。
  • GZ组(20<CL≤35.7)淀粉样蛋白累积率最高,为5.1 CL/年。

核心结论

  • 基线淀粉样蛋白水平可区分随时间累积淀粉样蛋白并存在认知下降风险的个体,包括亚阈值Aβ水平者,有助于在SCD人群中识别临床前AD。

研究设计与样本

  • 来自Fundació ACE健康脑倡议的197例SCD个体中,118例完成三次[18F]florbetaben扫描、79例完成两次扫描,跨度5年。
  • 按基线Centiloid值分组:Aβ+(CL>35.7)、灰区GZ(20<CL≤35.7)、Aβ-(CL≤20);Aβ-组再分为N1(CL≤13.5)和N2(13.5<CL≤20)。
  • 评估基线淀粉样蛋白水平与MCI转化的关系,并分析N1组淀粉样蛋白累积者的参数图像。

主要发现

  • 基线时Aβ+组20例、GZ组8例、N1组160例、N2组9例。
  • 淀粉样蛋白负荷较高、年龄较大和受教育程度较低的个体MCI转化风险增加。
  • N1组19%个体尽管基线Aβ负荷很低仍出现累积;N2组89%累积;GZ组全部累积,累积率最高为5.1 CL/年。
  • N1组累积者的参数图像分析显示楔前叶内一个区域与Aβ随时间增加相关。

关键数值与推荐

  • Aβ+定义为CL>35.7,GZ定义为20<CL≤35.7,Aβ-定义为CL≤20。
  • Aβ-组分为N1(CL≤13.5)和N2(13.5<CL≤20)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Amyloid PET imaging is capable of measuring brain amyloid load in vivo. The aim of this study is to assess the relationship of the baseline amyloid with its accumulation over time and with cognition in individuals with subjective cognitive decline (SCD), giving a focus on those below Aβ positivity thresholds. METHODS: 118 of 197 individuals with SCD from the Fundació ACE Healthy Brain Initiative underwent three [18F]florbetaben scans and the remaining 79 underwent two scans in a 5-year span. Individuals were categorised based on baseline Centiloid values (CL) into amyloid positive (Aβ+; CL > 35.7), Grey Zone (GZ; 20 < CL ≤ 35.7), and amyloid negative (Aβ-; CL ≤ 20). Relationship between conversion to mild cognitive decline (MCI) and baseline amyloid levels was assessed. Then, to focus on sub-threshold individuals with amyloid accumulation, the Aβ- group was split into two groups (N1 (CL ≤ 13.5) and N2 (13.5 < CL ≤ 20)), Aβ accumulation was determined, and a parametric image analysis of the Aβ accumulators in the N1 group was performed. RESULTS: At baseline, 20 individuals were Aβ+, 8 GZ, 160 N1, and 9 N2. Higher Aβ load, older and less educated individuals presented increased risk of MCI-conversion. Longitudinally, 19% of N1 individuals were accumulators despite very low Aβ burden at baseline. Meanwhile, 89% of the N2 group accumulated Aβ as well as all GZ individuals (which had the highest rate of amyloid accumulation, 5.1 CL/year). In the parametric image analysis of N1 accumulators, a region within the precuneus was linked to increased Aβ over time. CONCLUSION: Baseline amyloid levels differentiate individuals who accumulate amyloid over time and that are at risk for cognitive decline, including those at sub-threshold levels of Aβ. This can be valuable to identify pre-clinical AD in a SCD population.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kolinger GD, Sotolongo-Grau O, Roé-Vellvé N, et al. Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40263206. doi:10.1007/s00259-025-07270-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。